Group 1 - American Superconductor (AMSC) shares have increased by 35.4% in the past four weeks, closing at $27.38, with a mean price target of $39 indicating a potential upside of 42.4% [1] - The average price targets from analysts range from a low of $38 to a high of $40, with a standard deviation of $1, suggesting a strong agreement among analysts regarding the stock's potential movement [2] - Analysts are optimistic about AMSC's earnings prospects, as indicated by positive revisions in earnings estimates, which historically correlate with stock price movements [4][9] Group 2 - The Zacks Consensus Estimate for AMSC has increased by 2.5% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [10] - AMSC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [11] - While price targets may not be entirely reliable, the direction they imply can serve as a useful guide for investors [11]

Kezar Life Sciences, Inc. (KZR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Synchronoss (SNCR) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Synchronoss currently has an average br ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about AZZ (AZZ) .AZZ currently has an average brokerage recommendation (ABR) of 1.50, on a scale of 1 ...

Group 1 - BioCryst Pharmaceuticals (BCRX) closed at $10.59, with a 26.2% gain over the past four weeks, and a mean price target of $16.50 indicating a 55.8% upside potential [1] - The average of 12 short-term price targets ranges from a low of $11 to a high of $30, with a standard deviation of $5.32, suggesting variability in analyst estimates [2] - Analysts show strong agreement on BCRX's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 366.9% over the past month, with six estimates revised higher and no negative revisions [12] - BCRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting stock gains, they can indicate potential price movement direction [13]

Summit Therapeutics PLC (SMMT) closed the last trading session at $25.85, gaining 10.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $37.38 indicates a 44.6% upside potential.The average comprises eight short-term price targets ranging from a low of $30 to a high of $44, with a standard deviation of $5.71. While the lowest estimate indicates an increase of 16.1% from the current ...

Shares of Roku (ROKU) have gained 5% over the past four weeks to close the last trading session at $69.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $88.87 indicates a potential upside of 28.8%.The mean estimate comprises 26 short-term price targets with a standard deviation of $17.78. While the lowest estimate of $60 indicates a 13.1% decline from the current price level, ...

Core Viewpoint - Adeia (ADEA) shows potential for significant upside, with a mean price target of $17.33 indicating a 37% increase from its current price of $12.65 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $0.58, suggesting a consensus among analysts [2] - The lowest estimate of $17 indicates a 34.4% increase, while the highest estimate suggests a 42.3% increase to $18 [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about ADEA's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, one estimate has increased, leading to a 1% rise in the Zacks Consensus Estimate [12] - ADEA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research shows they rarely indicate actual price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [10]

Consensus Cloud Solutions, Inc. (CCSI) closed the last trading session at $21.37, gaining 10.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $27.40 indicates a 28.2% upside potential.The average comprises five short-term price targets ranging from a low of $20 to a high of $37, with a standard deviation of $7.06. While the lowest estimate indicates a decline of 6.4% from the cur ...

Copa Holdings (CPA) closed the last trading session at $106.47, gaining 17.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $152.73 indicates a 43.5% upside potential.The average comprises 11 short-term price targets ranging from a low of $125 to a high of $190, with a standard deviation of $19.78. While the lowest estimate indicates an increase of 17.4% from the current price le ...